Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
<p>Evaluation of circulating CD4+ T cell subsets. (A) Changes in regulatory T cells (Tregs) during treatment compared to screening in the entire patient cohort. (B) Changes in levels of circulating CD4+ naïve (CD45RA+ CCR7+), central memory (CM; CD45RA- CCR7+), effector memory (EM; CD45RA- CCR...
Saved in:
| 主要作者: | |
|---|---|
| 其他作者: | , , , , , , , , , , , , , , , , , , , , |
| 出版: |
2025
|
| 主題: | |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|